IONIS 2025 JPM Presentation_FINAL.pdf

1、The Next Chapter:Accelerating Value Through InnovationBrett P.Monia,Ph.D.,Chief Executive Officer JP Morgan Healthcare Conference|January 2025|Nasdaq:IONSForward-Looking StatementsThis presentation includes forward-looking statements regarding our business,financial guidance and the therapeutic and

2、commercial potential of our commercial medicines,additional medicines in development and technologies.Any statement describing Ionis goals,expectations,financial or other projections,intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.Such statements ar

3、e subject to certain risks and uncertainties including but not limited to those related to our commercial products and the medicines in our pipeline,and particularly those inherent in the process of discovering,developing and commercializing medicines that are safe and effective for use as human the

4、rapeutics,and in the endeavor of building a business around such medicines.Ionis forward-looking statements also involve assumptions that,if they never materialize or prove correct,could cause its results to differ materially from those expressed or implied by such forward-looking statements.Althoug

5、h Ionis forward-looking statements reflect the good faith judgment of its management,these statements are based only on facts and factors currently known by Ionis.Except as required by law,we undertake no obligation to update any forward-looking statements for any reason.As a result,you are cautione

6、d not to rely on these forward-looking statements.These and other risks concerning Ionis programs are described in additional detail in Ionis annual report on our Form 10-K for the year ended December 31,2023,and our most recent Form 10-Q quarterly filing,which are on file with the SEC.Copies of the